Similar articles

• Molecular engineering of cholera toxin.

  Burnette WN, Kaslow HR, Moss J. Burnette WN, et al. Adv Exp Med Biol. 1995;371B:1513-8. Adv Exp Med Biol. 1995. PMID: 7502847 Review. No abstract available.
• Construction and preclinical evaluation of recombinant Peru-15 expressing high levels of the cholera toxin B subunit as a vaccine against enterotoxigenic Escherichia coli.

  Roland KL, Cloninger C, Kochi SK, Thomas LJ, Tinge SA, Rouskey C, Killeen KP. Roland KL, et al. Vaccine. 2007 Dec 12;25(51):8574-84. doi: 10.1016/j.vaccine.2007.09.074. Epub 2007 Oct 26. Vaccine. 2007. PMID: 18045752
• Vaccination against the cholera/coli family of enterotoxins by synthetic peptides.

  Jacob CO. Jacob CO. Adv Biotechnol Processes. 1990;13:223-54. Adv Biotechnol Processes. 1990. PMID: 1692224 Review. No abstract available.
• Oral cholera vaccines: use in clinical practice.

  Hill DR, Ford L, Lalloo DG. Hill DR, et al. Lancet Infect Dis. 2006 Jun;6(6):361-73. doi: 10.1016/S1473-3099(06)70494-7. Lancet Infect Dis. 2006. PMID: 16728322 Review.
• [Cholera immunology and the molecular biology of cholera toxin. Recent progress and future prospects].

  Carrada Bravo T. Carrada Bravo T. Rev Alerg. 1993 Jul-Aug;40(4):91-4. Rev Alerg. 1993. PMID: 8143024 Review. Spanish.